As a leader in FcRn inhibitor technology, we are boldly developing innovative therapies for a range of debilitating auotimmune diseases with significant unmet patient needs. Our investigational products batoclimab (“IMVT-1401”) and IMVT-1402 are novel, fully human, monoclonal antibodies targeting the FcRn receptor. Both assets are in development as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.
All Other Basic Organic Chemical Manufacturing (325199)
Pharmaceutical Preparations (2834)
Chau Cheng, PhD, MBA
320 W 37th Street
New York, NY 10018